TDI-015051
TDI-015051 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 ≤0.15 nM. TDI-015051 inhibits SARS-CoV-2 NSP14 in Huh-7.5 cell (EC50=11.4 nM) and in ACE2-TMPRSS2 expressing A549 cell (EC50=64.7 nM) . TDI-015051 also inhibits other coronaviruses like α-hCoV-NL63, α-hCoV-229E and β-hCoV-MERS with IC50s of 1.7, 2.6 and 3.6 nM, respectively. TDI-015051 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and viral replication, and exhibits anti-infectious activity in mouse models[1].
Product Specifications
CAS Number
3052313-73-9
UNSPSC
12352005
Target
DNA Methyltransferase; SARS-CoV
Related Pathways
Anti-infection; Epigenetics
Applications
COVID-19-anti-virus
Field of Research
Infection
Smiles
O=S(N(CC1)CC2=C1NN=C2)(C3=C(C)N(C)C(C(NCC4=C(F)C=CC5=C4C=CO5)=O)=C3)=O
Molecular Formula
C22H22FN5O4S
Molecular Weight
471.50
References & Citations
[1]Meyer C, et al., Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase. Nature. 2024 Dec 11.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human IgG (Immunoglobulin Gamma Heavy Chain) (B-Cell Marker) (IG507R), 1mg/mL
Thyroid Stimulating Hormone, beta (TSH beta) (Pituitary Marker) (TSHb/1317), CF647 conjugate, 0.1mg/mL
